Prothena Corp. Plc (PRTA)

Prothena reported profitable first-quarter 2026 financial results with total revenue rising to $51.1 million, driven by a $50.0 million development milestone payment from Novo Nordisk related to coramitug. Novo Nordisk obtained Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR amyloidosis with cardiomyopathy. Citizens Jmp raised their price target on Prothena's stock from $19.00 to $20.00, maintaining a "market outperform" rating. Other analyst ratings include a "sell" rating from Weiss Ratings, a boosted price objective from Royal Bank of Canada from $11.00 to $12.00 with a "sector perform" rating, and Stifel Nicolaus setting a $19.00 price objective. Citigroup also reiterated an "outperform" rating. Prothena announced leadership team updates in April 2026. Prothena partners presented data supporting next-generation treatments for Parkinson's and Alzheimer's disease at AD/PD™ 2026 in March.

Prothena's products and services do not typically experience demand seasonality. The demand for its investigational therapies is driven by clinical trial progress, regulatory milestones, and the prevalence of the diseases it aims to treat, rather than seasonal consumer patterns. Direct demand seasonality for Prothena's specific products is not a reported factor.

Prothena Corporation Plc is a clinical-stage biotechnology company focused on discovering, developing, and commercializing novel therapies for diseases caused by protein misfolding and amyloidosis, particularly neurodegenerative and rare peripheral amyloid diseases. Prasinezumab is in Phase 3 clinical trials for Parkinson's disease and other synucleinopathies, developed with Roche. Coramitug (PRX004) is in Phase 3 clinical trials for transthyretin (ATTR) amyloidosis with cardiomyopathy, with Novo Nordisk obtaining Fast Track Designation from the U.S. FDA. BMS-986446 (PRX005) is an anti-tau antibody in Phase 2 clinical trials for Alzheimer's disease, developed with Bristol Myers Squibb. PRX019 is in Phase 1 clinical trials for neurodegenerative diseases. PRX123 is a Dual Aβ-Tau Vaccine in preclinical trials for treating Alzheimer's disease. TDP-43 CYTOPE is in discovery- and late-preclinical-stage for amyotrophic lateral sclerosis (ALS). PRX012 is a next-generation anti-Aβ antibody in Phase 1 clinical trials for Alzheimer's disease. PRX012-TfR is a preclinical program for the treatment of Alzheimer's disease.

Prothena Corporation Plc is headquartered in Dublin, Ireland, and maintains significant operations in the United States.

Prothena has a consensus "Hold" rating with a consensus target price of $21.78. One equities research analyst has rated the stock with a "Strong Buy," four have given a "Buy" rating, four have issued a "Hold" rating, and two have assigned a "Sell" rating. Recent positive financial results and milestone payments, along with FDA Fast Track designation for Coramitug, likely contribute positively to its reputation. No specific negative events directly impacting brand reputation beyond the inherent risks and challenges of drug development were prominently reported.

Prothena Corporation Plc has significant institutional ownership, with 193 institutional owners holding a total of 46,428,076 shares as of May 4, 2026. Major institutional shareholders include Fmr Llc, BlackRock, Inc., Rubric Capital Management LP, State Street Corp, Vanguard Group Inc, D. E. Shaw & Co., Inc., Armistice Capital, Llc, ADAR1 Capital Management, LLC, Acadian Asset Management Llc, and Morgan Stanley. Other notable institutional owners include Bank of New York Mellon Corp, Hsbc Holdings PLC, Strs Ohio, Invesco Ltd., Russell Investments Group Ltd., and Goldman Sachs Group Inc. Institutions hold approximately 76% of the company's shares.